Compare Ishares Msci Spain ETF (EWP) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Mesoblast Limited — how do they compare? Ishares Msci Spain ETF trades at $59.26, while Mesoblast Limited trades at $18.58 (market cap $2.31B). The key difference: Ishares Msci Spain ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| EWP | MESO | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $60.28 | $20.96 |
52-Week Low | $43.90 | $11.35 |
Market Cap | — | $2.31B |
Enterprise Value | — | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO is trading at $18.61, up 11.17% today, with strong technical momentum as moving averages signal bullish conditions. The company shows promising revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a -144.33% net income margin. Recent milestones include completing patient recruitment for a Phase 3 chronic low back pain trial and securing a $50 million non-dilutive facility.
The outlook is cautiously optimistic given strong analyst support (45% buy ratings) and commercial progress, but significant execution risks remain. Investors face high valuation multiples (P/S 30.52) and substantial cash burn despite reduced operating expenses. The stock's near-term direction will depend on clinical trial outcomes and revenue acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
